Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders.
Repurposing FDA-approved drugs may decrease fibrosis in butterfly disease
Repurposing FDA-approved drugs may decrease fibrosis in butterfly disease
"Recessive Dystrophic Epidermolysis Bullosa (RDEB) is the worst disease you've probably never heard of," says dermatology researcher Andrew South, Ph.D..
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate.
Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003
Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Prom...
Roche touts early trial success of second obesity drug candidate
Roche touts early trial success of second obesity drug candidate
Roche, opens new tab said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a la...
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
The company plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2. Two months after MSD (Merck & Co) set its eye on acquiring Eyebiotec...
Some diabetes drugs like Ozempic may lower risks of 10 cancers, study finds
Some diabetes drugs like Ozempic may lower risks of 10 cancers, study finds
Multiple factors contribute to someone’s risk of developing cancer. Obesity is one risk factor that can increase the risk of some cancer types. Researchers are interested in discovering strategies t...
NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
The subcutaneous formulation of Roche’s blockbuster Ocrevus will cut hospital treatment time for patients. England’s National Health Service (NHS) has said that multiple sclerosis patients...
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist Danuglipron
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist Danuglipron
Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile
AskBio secures FDA Fast Track designation for AB-1005 to treat PD
AskBio secures FDA Fast Track designation for AB-1005 to treat PD
AB-1005 is a gene therapy developed based on adeno-associated viral vector serotype 2 containing the human glial cell line-derived neurotrophic factor (AAV2-GDNF) transgene, evaluated as a pot...
FDA grants fast track designation to AskBio’s AB-1005 for PD
FDA grants fast track designation to AskBio’s AB-1005 for PD
AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.
Merz Therapeutics wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
Merz Therapeutics wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
The deal strengthens Merz’s market position in Parkinson’s disease while expanding into the multiple sclerosis sector.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand